Login to Your Account



Minding Lymphoma's Ps and Cs

Allos Well: Gloucester Buyout Not 'ASH' Bad as Some Fear

By Randy Osborne


Monday, December 14, 2009
Allos Therapeutics Inc.'s stock drop last week after Celgene Corp. disclosed its plan to buy out competitor Gloucester Pharmaceuticals Inc. seemed to signal investor nail-biting over the market chances for Allos' recently approved peripheral T-cell lymphoma drug Folotyn, due to fully launch in the first quarter of next year. (BioWorld Insight)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription